AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) stock enjoyed an overall uptrend of 17.32% from the beginning of 2019. The closing share price quoted for January 10, 2019 was $2.71. The -1.45% drop might have been tempting for an investor to sell at this point but in fact that would prove a short-sighted mistake, as sell-side analysts think there is almost 269% more gain yet to come for shareholders. Analysts seemed to set $10 as highest price target on its way to greater gains. The average 12-month price target they expect from the stock is $8.67. This mean price target represents 219.93% upside over its previous closing price. The median price target they presented was $9 for the next 12-months, which suggests a 232.1% upside from current levels. Some analysts have a lowest price target on the stock of $7, which would mean a 158.3% gain in value.
A fresh roundup today notes that ACRX stock has added around 27.53% of its value in the past 12 months, suggesting more investors have expressed joy over about in that time period. If we turn to the Street in general, the positives still outweigh the negatives as we can see that AcelRx Pharmaceuticals, Inc. (ACRX), have a buy (2) analyst consensus rating. In the current time, the stock has 6 buy and 2 hold ratings. The stock registered its 52-week high of $5.05 on February 11 and its 52-week low of $1.65 on July 03. Currently, the shares are trading $0.02 above its YTD moving average of $2.69.
Moving on, AcelRx Pharmaceuticals, Inc. (ACRX) last reported its September 2018 earnings. For brief highlights, it performed weak in that quarter, with earnings down -25% year-over-year at $-0.21. The company surprised analysts by 0 who were expecting $-0.21 per share. Overall, its quarterly revenues dropped by -74% to reach $380000, while it had reported $1.49 million in the same period a year ago. To see what investors should really expect from its December 2018 financial results consensus analyst estimates are calling for current quarter earnings per share of $-0.2, down from $-0.2 in the same quarter a year ago. However, earnings-per-share are expected to see growth of -12.9% in next year. From there, the company believes it can achieve a long-term annual earnings growth rate of 0 %. At the other end of the income statement, we have seen revenue of $2.3 million over the trailing 12 months.
To help you decide whether it’s worth the wait (and the money), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is currently trading at 0X the company’s trailing-12-month earnings per share, which represents a discount compared to the sector’s 30.88X and comes in below its industry’s 95.96X. The most popular method for valuing a stock is to study the historic Price-to-Earnings (P/E) ratio using reported earnings for the past 12 months. The EPS number for this stock in the most recent four quarters of earnings stood at $-0.16. P/E ratio is so popular because it’s simple, it’s effective, and, tautologically, because everyone uses it.
The 14-day Absolute ATR (Average True Range) on Thursday, January 10 of 2019 shows that the price on average moves $0.22. The average daily volatility is 7.73% over the past week. Low volatility is good for the stock and it means we have calm and confident investors. If you check recent AcelRx Pharmaceuticals, Inc. (ACRX) volume, you will see that it has changed to 1.28 million shares versus the average daily volume of 4.11 million shares.
When you look at the daily chart for ACRX, you will observe the stock held -21.45% losses in the 6-month period and maintains 64.24% distance from its most recent low. The past 5-day performance for the share stays positive at 4.23% but up 5.63% from its three-week moving average. Comparing to 50-day SMA, AcelRx Pharmaceuticals, Inc. shares price is now down -14.02%. It also closed -13.57% lower from its 200-day SMA. This is often seen as the last line of defense for long term trends to find support at, else be considered broken and/or in a bear market. The daily chart of the stock more clearly reveals the slide in prices as it closed Thursday with a 1-month performance at -18.86%.